Leerink Partnrs Comments on Tandem Diabetes Care, Inc.’s FY2027 Earnings (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Stock analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Tandem Diabetes Care in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will post earnings per share of ($0.01) for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2028 earnings at $0.27 EPS.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Thursday, August 1st. The medical device company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $221.90 million for the quarter, compared to analysts’ expectations of $205.63 million. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.30) EPS.

Several other analysts have also recently commented on TNDM. Barclays raised their target price on Tandem Diabetes Care from $55.00 to $58.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Morgan Stanley reissued an “equal weight” rating and set a $45.00 price target on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Canaccord Genuity Group assumed coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They issued a “buy” rating and a $57.00 price objective for the company. Royal Bank of Canada began coverage on shares of Tandem Diabetes Care in a research note on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 target price on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 price target for the company. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $55.13.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $37.50 on Thursday. The firm’s 50 day moving average is $42.06 and its two-hundred day moving average is $41.89. The firm has a market capitalization of $2.45 billion, a P/E ratio of -17.94 and a beta of 1.33. The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $53.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TNDM. ORG Wealth Partners LLC purchased a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $30,000. ORG Partners LLC acquired a new stake in shares of Tandem Diabetes Care in the second quarter worth $31,000. Headlands Technologies LLC purchased a new position in shares of Tandem Diabetes Care during the first quarter valued at $35,000. MCF Advisors LLC raised its position in Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares during the period. Finally, Daiwa Securities Group Inc. purchased a new stake in Tandem Diabetes Care in the 2nd quarter worth about $86,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.